These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 33568538)

  • 1. Amyloid PET Imaging in Self-Identified Non-Hispanic Black Participants of the Anti-Amyloid in Asymptomatic Alzheimer's Disease (A4) Study.
    Deters KD; Napolioni V; Sperling RA; Greicius MD; Mayeux R; Hohman T; Mormino EC
    Neurology; 2021 Mar; 96(11):e1491-e1500. PubMed ID: 33568538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between Plasma P-Tau217 and Amyloid PET in Racial and Ethnic Underrepresented Groups (RE-URG) Compared with Non RE-URG in LEARN and A4.
    Molina-Henry D; Langford O; Donohue MC; Raman R; Aisen P; Johnson KA; Rissman RA; Sperling R
    J Prev Alzheimers Dis; 2024; 11(4):831-837. PubMed ID: 39044491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apolipoprotein E and Alzheimer's disease pathology in African American older adults.
    Royse SK; Snitz BE; Hill AV; Reese AC; Roush RE; Kamboh MI; Bertolet M; Saeed A; Lopresti BJ; Villemagne VL; Lopez OL; Reis SE; Becker JT; Cohen AD
    Neurobiol Aging; 2024 Jul; 139():11-19. PubMed ID: 38582070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Racial and ethnic differences in plasma biomarker eligibility for a preclinical Alzheimer's disease trial.
    Molina-Henry DP; Raman R; Liu A; Langford O; Johnson K; Shum LK; Glover CM; Dhadda S; Irizarry M; Jimenez-Maggiora G; Braunstein JB; Yarasheski K; Venkatesh V; West T; Verghese PB; Rissman RA; Aisen P; Grill JD; Sperling RA
    Alzheimers Dement; 2024 Jun; 20(6):3827-3838. PubMed ID: 38629508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals.
    Sperling RA; Donohue MC; Raman R; Sun CK; Yaari R; Holdridge K; Siemers E; Johnson KA; Aisen PS;
    JAMA Neurol; 2020 Jun; 77(6):735-745. PubMed ID: 32250387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Blood-Based Plasma Biomarkers as Potential Markers of Amyloid Burden in Preclinical Alzheimer's Disease.
    Winston CN; Langford O; Levin N; Raman R; Yarasheski K; West T; Abdel-Latif S; Donohue M; Nakamura A; Toba K; Masters CL; Doecke J; Sperling RA; Aisen PS; Rissman RA
    J Alzheimers Dis; 2023; 92(1):95-107. PubMed ID: 36710683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. APOE allele frequencies in suspected non-amyloid pathophysiology (SNAP) and the prodromal stages of Alzheimer's Disease.
    Hohman TJ; Dumitrescu L; Oksol A; Wagener M; Gifford KA; Jefferson AL;
    PLoS One; 2017; 12(11):e0188501. PubMed ID: 29190651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disparities by Race and Ethnicity Among Adults Recruited for a Preclinical Alzheimer Disease Trial.
    Raman R; Quiroz YT; Langford O; Choi J; Ritchie M; Baumgartner M; Rentz D; Aggarwal NT; Aisen P; Sperling R; Grill JD
    JAMA Netw Open; 2021 Jul; 4(7):e2114364. PubMed ID: 34228129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eligibility Rates among Racially and Ethnically Diverse US Participants in Phase 2 and Phase 3 Placebo-Controlled, Double-Blind, Randomized Trials of Lecanemab and Elenbecestat in Early Alzheimer Disease.
    Grill JD; Flournoy C; Dhadda S; Ernstrom K; Sperling R; Molina-Henry D; Tranotti K; Harris R; Kanekiyo M; Gee M; Irizarry M; Kramer L; Aisen P; Raman R
    Ann Neurol; 2024 Feb; 95(2):288-298. PubMed ID: 37830926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of Ptau181 Among a Diverse Community-Based Cohort: A HABS-HD Study.
    Petersen ME; Zhang F; Hall JR; Julovich D; Rissman RA; Meeker KL; Phillips N; Large S; Ances BM; O'Bryant SE;
    J Alzheimers Dis; 2024; 100(s1):S63-S73. PubMed ID: 39177606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma amyloid assay as a pre-screening tool for amyloid positron emission tomography imaging in early stage Alzheimer's disease.
    Lin SY; Lin KJ; Lin PC; Huang CC; Chang CC; Lee YC; Hsiao IT; Yen TC; Huang WS; Yang BH; Wang PN
    Alzheimers Res Ther; 2019 Dec; 11(1):111. PubMed ID: 31881963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient Characteristics at Prostate Cancer Diagnosis in Different Races at an Academic Center Serving a Diverse Population.
    Suresh T; Sharma J; Goel S; Kovac E; Gao Q; Gartrell B
    Clin Genitourin Cancer; 2019 Apr; 17(2):139-144. PubMed ID: 30655076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons.
    Knopman DS; Jack CR; Wiste HJ; Lundt ES; Weigand SD; Vemuri P; Lowe VJ; Kantarci K; Gunter JL; Senjem ML; Mielke MM; Roberts RO; Boeve BF; Petersen RC
    Neurobiol Aging; 2014 Sep; 35(9):2096-106. PubMed ID: 24702820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Depression is Associated with Tau and Not Amyloid Positron Emission Tomography in Cognitively Normal Adults.
    Babulal GM; Roe CM; Stout SH; Rajasekar G; Wisch JK; Benzinger TLS; Morris JC; Ances BM
    J Alzheimers Dis; 2020; 74(4):1045-1055. PubMed ID: 32144985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myo-inositol changes precede amyloid pathology and relate to APOE genotype in Alzheimer disease.
    Voevodskaya O; Sundgren PC; Strandberg O; Zetterberg H; Minthon L; Blennow K; Wahlund LO; Westman E; Hansson O;
    Neurology; 2016 May; 86(19):1754-61. PubMed ID: 27164711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease.
    Drzezga A; Grimmer T; Henriksen G; Mühlau M; Perneczky R; Miederer I; Praus C; Sorg C; Wohlschläger A; Riemenschneider M; Wester HJ; Foerstl H; Schwaiger M; Kurz A
    Neurology; 2009 Apr; 72(17):1487-94. PubMed ID: 19339712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-Randomization Predictors of Study Discontinuation in a Preclinical Alzheimer's Disease Randomized Controlled Trial.
    Raman R; Hussen K; Donohue MC; Ernstrom K; Holdridge KC; Langford O; Molina-Henry DP; Pierce AL; Sims JR; Smith A; Yaari R; Aisen PS; Sperling R; Grill JD
    J Prev Alzheimers Dis; 2024; 11(4):874-880. PubMed ID: 39044496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
    Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
    Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigating the Factor Structure of the Preclinical Alzheimer Cognitive Composite and Cognitive Function Index across Racial/Ethnic, Sex, and Aβ Status Groups in the A4 Study.
    Ruthirakuhan M; Wood Alexander M; Cogo-Moreira H; Robinson T; Amariglio R; Buckley RF; Sperling RA; Swardfager W; Black SE; Rabin JS
    J Prev Alzheimers Dis; 2024; 11(1):48-55. PubMed ID: 38230716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.